AZD8205: "AZD8205 - promising efficacy in heavily pre-treated patients with ovarian, breast and endometrial cancer"; Solid tumors (AstraZeneca) - Sep 17, 2024 - ESMO 2024: "20.5% ORR with doses ≥1.6 mg/kg across B7-H4 levels"
P1/2 data • Breast Cancer • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor
|